Key result
Atenolol reduces blood pressure and platelet adhesion vs placebo but lowers HDL cholesterol.
Why the study?
Does atenolol 100 mg/day reduce blood pressure and platelet adhesion in patients with established hypertension?
RCT (n=14)
Double-blind
Does atenolol 100 mg/day reduce blood pressure and platelet adhesion in patients with established hypertension?
Atenolol effectively lowers blood pressure and reduces platelet adhesion in hypertensive patients, which may contribute to its cardioprotective effects, though it lowers HDL cholesterol.
Answers are grounded in this paper and cite their sources.
Supports atenolol for hypertension with platelet benefits; extends RCT data on its HDL-lowering effects.
Fourteen patients with established hypertension followed a double-blind crossover-styled trial to study the effects of 100 mg/day atenolol compared to placebo. Atenolol was found to be an effective antihypertensive agent, reducing both systolic and diastolic blood pressure. Hypertensive patients appear to have increased in vitro platelet adhesion and aggregation. Atenolol significantly reduced platelet adhesion, but had little effect on aggregation. This may be important in contributing towards the now-recognised cardio-protective effect of the beta-adrenoceptor blocking agents. Blood chemistry and haematological parameters were unchanged; but whereas plasma cholesterol and plasma triglyceride levels remained normal, there was a significant fall in plasma high-density lipoprotein cholesterol levels. Side effects were very few.
No takes yet. Share an insight, caveat, or question.
Markel et al. (1983) conducted an RCT in Hypertension (n=14). Atenolol vs. Placebo was evaluated on Platelet adhesion and aggregation. Atenolol /day reduced blood pressure and platelet adhesion in hypertensive patients compared to placebo, but also caused a significant fall in HDL cholesterol.
Synapse has enriched 10 related papers. Consider them for comparative context: